Download PDF
Semin Reprod Med 2010; 28(6): 513-518
DOI: 10.1055/s-0030-1265679
© Thieme Medical Publishers

Ovarian Hyperstimulation Syndrome Prevention Strategies: Cryopreservation of All Embryos

Arianna D'Angelo1
  • 1Consultant in Assisted Reproduction, IVF Wales; Clinical Lecturer, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, United Kingdom
Further Information

Publication History

Publication Date:
16 November 2010 (online)

    Permissions and Reprints

ABSTRACT

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic potentially life-threatening condition resulting from excessive ovarian stimulation. The crucial event in the development of OHSS is the administration of human chorionic gonadotropin (hCG). The early onset of OHSS typically presents in the luteal phase as a consequence of ovulatory hCG. The late onset of OHSS presents in early gestation when endogenous hCG further stimulates the ovary. Many strategies have been proposed for OHSS prevention, but they may reduce but not eliminate the risk. This article reviews the evidence related to the elective cryopreservation of all embryos and their subsequent transfer in women at risk of OHSS. More research is needed to determine whether using elective cryopreservation of embryos can reduce the rate of severe OHSS in in vitro insemination (IVF)/intracytoplasmic sperm injection (ICSI). Results from many retrospective studies are encouraging, but prevention in terms of (1) identification of the high-risk population using new biochemical markers of ovarian response such as anti-Müllerian hormone, (2) tailoring ovarian stimulation and using less aggressive protocols (gonadotropin-releasing hormone antagonists or mild IVF), and (3) blastocyst culture to allow clinical monitoring of early-onset OHSS, with eventual blastocyst cryopreservation, might represent a multistep approach worth further investigation.

KEYWORDS

OHSS - ovarian hyperstimulation syndrome - embryo freezing - cryopreservation - prevention

REFERENCES

  • 1 Forman R G, Frydman R, Egan D, Ross C, Barlow D H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.  Fertil Steril. 1990;  53(3) 502-509
    PubMedGoogle Scholar
  • 2 Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.  Fertil Steril. 1992;  58(2) 249-261
    PubMedGoogle Scholar
  • 3 Rabau E, David A, Serr D M, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment.  Am J Obstet Gynecol. 1967;  98(1) 92-98
    PubMedGoogle Scholar
  • 4 Schenker J G, Weinstein D. Ovarian hyperstimulation syndrome: a current survey.  Fertil Steril. 1978;  30(3) 255-268
    PubMedGoogle Scholar
  • 5 Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review.  Obstet Gynecol Surv. 1989;  44(6) 430-440
    CrossrefPubMedGoogle Scholar
  • 6 Lyons C A, Wheeler C A, Frishman G N, Hackett R J, Seifer D B, Haning Jr R V. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.  Hum Reprod. 1994;  9(5) 792-799
    PubMedGoogle Scholar
  • 7 Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer.  Obstet Gynecol. 1993;  81(6) 1009-1011
    PubMedGoogle Scholar
  • 8 Egbase P E, Sharhan M A, Grudzinskas J G. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.  Hum Reprod. 1999;  14(6) 1421-1425
    CrossrefPubMedGoogle Scholar
  • 9 Araujo Jr E, Bernardini L, Frederick J L, Asch R H, Balmaceda J P. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.  J Assist Reprod Genet. 1994;  11(2) 74-78
    CrossrefPubMedGoogle Scholar
  • 10 Gonen Y, Balakier H, Powell W, Casper R F. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.  J Clin Endocrinol Metab. 1990;  71(4) 918-922
    CrossrefPubMedGoogle Scholar
  • 11 Kinget K, Nijs M, Cox A M et al. A novel approach for patients at risk for ovarian hyperstimulation syndrome: elective transfer of a single zona-free blastocyst on day 5.  Reprod Biomed Online. 2002;  4(1) 51-55
    CrossrefPubMedGoogle Scholar
  • 12 Ata B, Yakin K, Alatas C, Urman B. Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome.  Fertil Steril. 2008;  90(3) 531-536
    CrossrefPubMedGoogle Scholar
  • 13 Amso N N, Ahuja K K, Morris N, Shaw R W. The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos.  Fertil Steril. 1990;  53(6) 1087-1090
    PubMedGoogle Scholar
  • 14 Awonuga A O, Pittrof R J, Zaidi J, Dean N, Jacobs H S, Tan S L. Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate.  J Assist Reprod Genet. 1996;  13(5) 401-406
    CrossrefPubMedGoogle Scholar
  • 15 Fitzmaurice G J, Boylan C, McClure N. Are pregnancy rates compromised following embryo freezing to prevent OHSS?.  Ulster Med J. 2008;  77(3) 164-167
    PubMedGoogle Scholar
  • 16 D'Angelo A, Amso N N. Embryo freezing for preventing ovarian hyperstimulation syndrome.  Cochrane Database Syst Rev. 2007;  (3) CD002806
    PubMedGoogle Scholar
  • 17 Shaker A G, Zosmer A, Dean N, Bekir J S, Jacobs H S, Tan S L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 1996;  65(5) 992-996
    PubMedGoogle Scholar
  • 18 Ferraretti A P, Gianaroli L, Magli C, Fortini D, Selman H A, Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety.  Hum Reprod. 1999;  14(6) 1457-1460
    CrossrefPubMedGoogle Scholar
  • 19 Aboulghar M, Evers J H, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome.  Cochrane Database Syst Rev. 1999;  (4)
    PubMedGoogle Scholar
  • 20 Granne I, Child T, Hartshorne G. Embryo cryopreservation: evidence for practice.  Hum Fertil (Camb). 2008;  11(3) 159-172
    CrossrefPubMedGoogle Scholar
  • 21 Eftekhari-Yazdi P, Valojerdi M R, Ashtiani S K, Eslaminejad M B, Karimian L. Effect of fragment removal on blastocyst formation and quality of human embryos.  Reprod Biomed Online. 2006;  13(6) 823-832
    CrossrefPubMedGoogle Scholar
  • 22 Lewis S E, West M C, Fleming R. Sperm and embryo cryopreservation practice in licensed clinics in the UK endorsed by The British Fertility Society.  Hum Fertil (Camb). 2006;  9(1) 15-26
    CrossrefPubMedGoogle Scholar
  • 23 Menezo Y. Cryopreservation of IVF embryos: which stage?.  Eur J Obstet Gynecol Reprod Biol. 2004;  113(Suppl 1) S28-S32
    CrossrefPubMedGoogle Scholar
  • 24 Hoover L, Baker A, Check J H, Lurie D, Summers D. Clinical outcome of cryopreserved human pronuclear stage embryos resulting from intracytoplasmic sperm injection.  Fertil Steril. 1997;  67(4) 621-624
    CrossrefPubMedGoogle Scholar
  • 25 Oatway C, Gunby J, Daya S. Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection.  Cochrane Database Syst Rev. 2004;  (2) CD004378
    PubMedGoogle Scholar
  • 26 Gardner D K. Development of serum-free media for the culture and transfer of human blastocysts.  Hum Reprod. 1998;  13(Suppl 4) 218-225
    PubMedGoogle Scholar
  • 27 Hartshorne G M, Elder K, Crow J, Dyson H, Edwards R G. The influence of in-vitro development upon post-thaw survival and implantation of cryopreserved human blastocysts.  Hum Reprod. 1991;  6(1) 136-141
    PubMedGoogle Scholar
  • 28 Veeck L L, Bodine R, Clarke R N et al. High pregnancy rates can be achieved after freezing and thawing human blastocysts.  Fertil Steril. 2004;  82(5) 1418-1427
    CrossrefPubMedGoogle Scholar
  • 29 Fuller B, Paynter S. Fundamentals of cryobiology in reproductive medicine.  Reprod Biomed Online. 2004;  9(6) 680-691
    CrossrefPubMedGoogle Scholar
  • 30 Blake D, Proctor M, Johnson N, Olive D. Cleavage stage versus blastocyst stage embryo transfer in assisted conception.  Cochrane Database Syst Rev. 2005;  (4) CD002118
    PubMedGoogle Scholar
  • 31 Selman H, Brusco G F, Fiorini F, Barnocchi N, Mariani M, El-Danasouri I. Vitrification is a highly efficient method to cryopreserve human embryos in in vitro fertilization patients at high risk of developing ovarian hyperstimulation syndrome.  Fertil Steril. 2009;  91(4, Suppl) 1611-1613
    CrossrefPubMedGoogle Scholar
  • 32 Wennerholm U B, Hamberger L, Nilsson L, Wennergren M, Wikland M, Bergh C. Obstetric and perinatal outcome of children conceived from cryopreserved embryos.  Hum Reprod. 1997;  12(8) 1819-1825
    CrossrefPubMedGoogle Scholar
  • 33 Al-Inany H G, Abu-Seta A M, Aboulgher M. Gonadotrpophin-releasing hromone antoagonists for assisted conception.  Cochran Database of Systematic Review. 2006;  issue 3
    PubMedGoogle Scholar

Arianna D'AngeloM.D. 

Consultant in Assisted Reproduction, IVF Wales; Clinical Lecturer

Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom

Email: dangeloa@cardiff.ac.uk

      >